RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,863,760 | -11.8% | 2,335,132 | -13.9% | 0.70% | -1.0% |
| Q2 2023 | $20,252,276 | +9.6% | 2,711,148 | -2.1% | 0.70% | +9.5% |
| Q1 2023 | $18,478,908 | -11.6% | 2,770,451 | +2.2% | 0.64% | -19.3% |
| Q4 2022 | $20,896,714 | -12.8% | 2,710,339 | +20.4% | 0.80% | -20.4% |
| Q3 2022 | $23,961,000 | +16.1% | 2,251,971 | -11.2% | 1.00% | +28.0% |
| Q2 2022 | $20,640,000 | +34.9% | 2,535,622 | +18.7% | 0.78% | +66.2% |
| Q1 2022 | $15,298,000 | -38.1% | 2,136,604 | +48.0% | 0.47% | -31.7% |
| Q4 2021 | $24,733,000 | +62.4% | 1,443,863 | +118.2% | 0.69% | +60.4% |
| Q3 2021 | $15,226,000 | -11.7% | 661,703 | +40.0% | 0.43% | +7.5% |
| Q2 2021 | $17,248,000 | – | 472,552 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |